Do you recommend adjuvant radiation therapy for resected spine metastases in NSCLC with targetable mutations?   

For example, EGFR-mutated de novo metastatic disease, do you offer adjuvant RT vs observation with targeted therapy alone?



Answer from: Radiation Oncologist at Community Practice